Chemotherapy-induced nausea and vomiting in routine practice:: a European perspective

被引:76
作者
Glaus, A
Knipping, C
Morant, R
Böhme, C
Lebert, B
Beldermann, F
Glawogger, B
Ortega, P
Hüsler, A
Deuson, R
机构
[1] Zentrum Tumordiagnost & Pravent, CH-9006 St Gallen, Switzerland
[2] Kantonsspital, Dept Innere Med, CH-9007 St Gallen, Switzerland
[3] Univ Klinikum Heidelberg, D-69120 Heidelberg, Germany
[4] Graz Univ, Med Klin, LKH Univ Klinikum, A-8036 Graz, Austria
[5] Inst Catala Oncol ICO, Barcelona 08907, Spain
[6] Univ Bern, Inst Math Stat & Versicherungslehre, CH-3012 Bern, Switzerland
[7] Merck & Co Inc, Whitehouse Stn, NJ 08889 USA
关键词
nausea/emesis; cancer treatment; antiemetic therapy; patient-reported outcomes;
D O I
10.1007/s00520-004-0662-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Goals of work: The aim of this study was to evaluate the occurrence of chemotherapy-induced nausea and vomiting (CINV) and its effect on patients' ability to carry out daily life activities following moderately to highly emetogenic, first-cycle chemotherapy in routine practice in cancer centers of four different European countries. Patients and methods: This was a prospective, cross-sectional, nonrandomized, self-assessment study in 249 patients enrolled from cancer centers in Spain, Austria, Germany, and Switzerland. The study population consisted of 78% women, with a mean age of 54. Breast, lung, and ovarian cancers made up 75% of all cancers in the study. Patients received a mean of 2.0 chemotherapy agents and 2.5 antiemetic drugs. Main results: A total of 450 emetic episodes experienced by 243 patients was recorded over 5 days following chemotherapy, with an average of 1.8 episodes per patient (range: 0-28). A higher percentage of patients (38%) suffered from delayed compared to acute emesis (13%). Between 42% and 52% of all patients suffered from nausea (visual analogue scale greater than or equal to5 mm) on any one day, peaking at day 3. Using the Functional Living Index for Emesis (FLIE) questionnaire, 75% of patients with nausea and 50% with vomiting reported a negative impact of these conditions on performance of daily living. Conclusions: CINV remains a significant problem in routine practice, particularly in the delayed phase posttreatment. Overall, CINV had a negative impact on patients' daily life.
引用
收藏
页码:708 / 715
页数:8
相关论文
共 50 条
[41]   Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study [J].
Suzuki-Chiba, Hiroe ;
Konishi, Takaaki ;
Aso, Shotaro ;
Makito, Kanako ;
Matsui, Hiroki ;
Jo, Taisuke ;
Fushimi, Kiyohide ;
Yasunaga, Hideo .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (11) :1762-1773
[42]   A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study [J].
Navari, Rudolph M. ;
Einhorn, Lawrence H. ;
Loehrer, Patrick J., Sr. ;
Passik, Steven D. ;
Vinson, Jake ;
McClean, John ;
Chowhan, Naveed ;
Hanna, Nasser H. ;
Johnson, Cynthia S. .
SUPPORTIVE CARE IN CANCER, 2007, 15 (11) :1285-1291
[43]   Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial [J].
Wu, Zihong ;
Fu, Xi ;
Jing, Hailiang ;
Huang, Wenbo ;
Li, Xueke ;
Xiao, Chong ;
Li, Zhuohong ;
You, Fengming .
JOURNAL OF ETHNOPHARMACOLOGY, 2024, 325
[44]   Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey [J].
Aapro, Matti ;
Ruffo, Pierfrancesco ;
Panteri, Roger ;
Costa, Stefano ;
Piovesana, Vittoria .
CANCER REPORTS, 2018, 1 (04)
[45]   Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy [J].
Ranganath, Praveen ;
Einhorn, Lawrence ;
Albany, Costantine .
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[46]   Tropisetron: Optimal dosage for children in prevention of chemotherapy-induced vomiting [J].
Cappelli, C ;
Ragni, G ;
De Pasquale, MD ;
Gonfiantini, M ;
Russo, D ;
Clerico, A .
PEDIATRIC BLOOD & CANCER, 2005, 45 (01) :48-53
[47]   Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting [J].
Alzahrani, Mashari Jemaan ;
Dranitsaris, George ;
Sienkiewicz, Marta ;
Vandermeer, Lisa ;
Clemons, Mark .
SUPPORTIVE CARE IN CANCER, 2021, 29 (12) :7837-7843
[48]   Pediatric oncology provider perspectives and patient/family perceptions of chemotherapy-induced nausea and vomiting management: Experiences at an academic medical center [J].
Bloomhardt, Hadley ;
Rubin, Melissa ;
Xue, Yanling ;
Jin, Zhezhen ;
Masino, Laura ;
Seidel, Drew ;
Hijiya, Nobuko ;
Beauchemin, Melissa .
PEDIATRIC BLOOD & CANCER, 2024, 71 (04)
[49]   Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting [J].
Thomas A. Burke ;
Tami Wisniewski ;
Frank R. Ernst .
Supportive Care in Cancer, 2011, 19 :131-140
[50]   Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting [J].
Burke, Thomas A. ;
Wisniewski, Tami ;
Ernst, Frank R. .
SUPPORTIVE CARE IN CANCER, 2011, 19 (01) :131-140